JP7464940B2 - Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same - Google Patents
Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same Download PDFInfo
- Publication number
- JP7464940B2 JP7464940B2 JP2020069744A JP2020069744A JP7464940B2 JP 7464940 B2 JP7464940 B2 JP 7464940B2 JP 2020069744 A JP2020069744 A JP 2020069744A JP 2020069744 A JP2020069744 A JP 2020069744A JP 7464940 B2 JP7464940 B2 JP 7464940B2
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- lactobacillus
- acid bacteria
- onion
- onions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000002732 Allium cepa var. cepa Nutrition 0.000 title claims description 83
- JYMHODZXTIGVPA-UHFFFAOYSA-N Cycloalliin Chemical compound CC1CS(=O)CC(C(O)=O)N1 JYMHODZXTIGVPA-UHFFFAOYSA-N 0.000 title claims description 72
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims description 57
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims description 54
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 241000234282 Allium Species 0.000 title claims 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 168
- 239000004310 lactic acid Substances 0.000 claims description 84
- 235000014655 lactic acid Nutrition 0.000 claims description 84
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- 241000894006 Bacteria Species 0.000 claims description 41
- 239000007787 solid Substances 0.000 claims description 31
- 229940072113 onion extract Drugs 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 15
- 235000013922 glutamic acid Nutrition 0.000 claims description 15
- 239000004220 glutamic acid Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 229940041514 candida albicans extract Drugs 0.000 claims description 13
- 239000012138 yeast extract Substances 0.000 claims description 13
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims description 12
- 240000001929 Lactobacillus brevis Species 0.000 claims description 11
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 11
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 6
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 241001468179 Enterococcus avium Species 0.000 claims description 3
- 241001522957 Enterococcus casseliflavus Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 3
- 241000186685 Lactobacillus hilgardii Species 0.000 claims description 3
- 241001134654 Lactobacillus leichmannii Species 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 3
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 3
- 244000057717 Streptococcus lactis Species 0.000 claims description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 235000021307 Triticum Nutrition 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 3
- 235000021119 whey protein Nutrition 0.000 claims description 3
- 229910001437 manganese ion Inorganic materials 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 241000209140 Triticum Species 0.000 claims 1
- 244000291564 Allium cepa Species 0.000 description 80
- 238000000855 fermentation Methods 0.000 description 39
- 230000004151 fermentation Effects 0.000 description 39
- 239000002609 medium Substances 0.000 description 32
- 229960002989 glutamic acid Drugs 0.000 description 16
- 235000013305 food Nutrition 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229910021645 metal ion Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- -1 iron ions Chemical class 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000011572 manganese Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- GJBHGUUFMNITCI-QTNFYWBSSA-M sodium;(2s)-2-aminopentanedioate;hydron;hydrate Chemical compound O.[Na+].OC(=O)[C@@H](N)CCC([O-])=O GJBHGUUFMNITCI-QTNFYWBSSA-M 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 239000004223 monosodium glutamate Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000007738 vacuum evaporation Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000020190 Azalea indica Species 0.000 description 1
- 235000002498 Azalea indica Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000270288 Gekko Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000019503 curry powder Nutrition 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Description
本発明は、加熱したタマネギを所定の条件下にて乳酸発酵して得らえる、γ-アミノ酪酸(以下、「GABA」と記載する)を含有し、かつシクロアリイン等の機能性成分が富化された乳酸菌発酵タマネギ、及びその製造方法に関する。 The present invention relates to lactic acid bacteria-fermented onions, which are obtained by lactic acid fermentation of heated onions under specific conditions and contain gamma-aminobutyric acid (hereinafter referred to as "GABA") and are enriched with functional components such as cycloalliin, and to a method for producing the same.
近年、生活習慣病の予防や健康維持に対する関心が高まり、関連する研究が数多く実施されており、果実や野菜等に含まれる、又はそれらに由来する天然成分への注目が高まっている。 In recent years, interest in preventing lifestyle-related diseases and maintaining health has increased, and many related studies have been conducted, with increasing attention being paid to natural ingredients contained in or derived from fruits, vegetables, etc.
例えば、タマネギは世界中で食されている野菜であり、疾病予防や健康維持に関する研究も進んでいる。タマネギ中に含まれる機能性成分の主なものとして、抗酸化作用を持つシクロアリインが挙げられる。生体内において活性酸素が過剰に産生されると、細胞内で脂質、タンパク質、DNA等を酸化して細胞死を誘発し老化や生活習慣病を引き起こしたり、また活性酸素により酸化されたLDL-コレステロールは、アテローム性動脈硬化を引き起こしたりする一因になるといわれている。このため、抗酸化作用を持つシクロアリインへの関心は高い。シクロアリインは、タマネギの鱗茎部にシクロアリイン前駆体として存在しており、90℃以上に加熱されることで前駆体構造が環状化され、シクロアリインが形成される(特許文献1)。また、タマネギについては、乳酸発酵することにより、α-グルコシダーゼ阻害活性やリパーゼ阻害活性、ラジカル消去活性といった生理活性が高まることも報告されている(特許文献2)。 For example, onions are a vegetable eaten worldwide, and research into disease prevention and health maintenance is also progressing. Cycloalliin, which has antioxidant properties, is one of the main functional components contained in onions. When active oxygen is produced excessively in the body, it oxidizes lipids, proteins, DNA, etc. in cells, inducing cell death and causing aging and lifestyle-related diseases, and it is said that LDL-cholesterol oxidized by active oxygen is one of the factors that cause atherosclerosis. For this reason, there is a lot of interest in cycloalliin, which has antioxidant properties. Cycloalliin exists in the bulb part of onions as a cycloalliin precursor, and when heated to 90°C or higher, the precursor structure is cyclized to form cycloalliin (Patent Document 1). It has also been reported that lactic acid fermentation of onions increases their physiological activities, such as α-glucosidase inhibitory activity, lipase inhibitory activity, and radical scavenging activity (Patent Document 2).
さらに、ミカン、モモ、ブドウ、イチゴ、ナシ等の果実や、ニンジン、トマト等の野菜、等の植物又はその汁液を乳酸発酵させ、GABAを含有する発酵物を製造する方法が報告されている(特許文献3)。GABAは、グルタミン酸を脱炭酸反応することで生成される非タンパク質性アミノ酸であり、高血圧症状の緩和に有効であることが知られているほか、近年はストレスの抑制や睡眠改善にも効果を有することが確認されている。これらの様々な有効性への期待から、GABAは機能性食品やサプリメント等の有効成分として利用され、その需要は大きくなっている。GABAは高いグルタミン酸脱炭酸酵素(以下、「GAD」と略記する)活性を有する乳酸菌を用いた、グルタミン酸を基質とする乳酸発酵により生産することができる(非特許文献1,2)。しかしながら、当該分野においてはGABAを効率的に摂取可能な新たな食品素材の開発が依然として切望されている。 Furthermore, a method has been reported in which fermentation of fruits such as mandarin oranges, peaches, grapes, strawberries, and pears, and vegetables such as carrots and tomatoes, or the juices thereof, is carried out to produce a fermented product containing GABA (Patent Document 3). GABA is a non-protein amino acid produced by decarboxylation of glutamic acid, and is known to be effective in alleviating hypertension symptoms. In addition, in recent years, it has been confirmed to be effective in suppressing stress and improving sleep. In anticipation of these various efficacies, GABA is used as an active ingredient in functional foods and supplements, and the demand for it is increasing. GABA can be produced by lactic acid fermentation using glutamic acid as a substrate, using lactic acid bacteria with high glutamic acid decarboxylase (hereinafter abbreviated as "GAD") activity (Non-Patent Documents 1 and 2). However, there is still a strong demand in this field for the development of new food materials that allow efficient intake of GABA.
上述のミカン、モモ、ブドウ、イチゴ、ナシ等の果実や、ニンジン、トマト等の野菜と異なり、タマネギ単独を原料として乳酸発酵によりGABAを生産することは不可能であった。また、タマネギには元来、糖質が多く含まれることから、シクロアリイン等の機能性成分を有効量摂取するためには糖質を過剰摂取してしまうことが懸念されていた。 Unlike the above-mentioned fruits such as mandarin oranges, peaches, grapes, strawberries, and pears, and vegetables such as carrots and tomatoes, it was not possible to produce GABA by lactic acid fermentation using onions alone as a raw material. Also, because onions naturally contain a lot of carbohydrates, there was concern that taking in an effective amount of functional ingredients such as cycloalliin would result in taking in too much carbohydrate.
そこで本発明は、タマネギを原料としてGABAを生産する方法を提供すると共に、タマネギ中の糖質含量を低減し、シクロアリイン等の機能性成分を富化する方法を提供することを目的とする。 The present invention aims to provide a method for producing GABA using onions as a raw material, as well as a method for reducing the carbohydrate content in onions and enriching them with functional components such as cycloalliin.
本発明者らは上記課題を解決すべく鋭意検討した結果、加熱したタマネギを窒素源及びグルタミン酸もしくはその塩の存在下にて、GAD活性を有する乳酸菌を用いて乳酸発酵することにより得られた乳酸菌発酵タマネギが、高含有量にてGABAを有し、かつ糖質等の可溶性固形分の含量が低減されシクロアリイン等の機能性成分が富化されていることを見出した。 As a result of intensive studies to solve the above problems, the present inventors have found that lactic acid bacteria-fermented onions, obtained by lactic acid fermentation of heated onions in the presence of a nitrogen source and glutamic acid or a salt thereof using lactic acid bacteria having GAD activity, have a high content of GABA, a reduced content of soluble solids such as carbohydrates, and are enriched in functional components such as cycloalliin.
本発明はこれらの知見に基づくものであり、以下の発明を有する。
[1] γ-アミノ酪酸(GABA)をタマネギのBrix固形含量当たり5w/w%以上含有することを特徴とする乳酸菌発酵タマネギ。
[2] さらに、シクロアリインをタマネギのBrix固形含量当たり0.5w/w%以上含有する、[1]の乳酸菌発酵タマネギ。
[3] タマネギがタマネギエキスである、[1]又は[2]の乳酸菌発酵タマネギ。
[4] 加熱したタマネギ、窒素源、及びグルタミン酸もしくはその塩を含む培地中にて、グルタミン酸脱炭酸酵素活性を有する乳酸菌を培養する工程を含む、GABAを含有する乳酸菌発酵タマネギの製造方法。
[5] 前記乳酸菌がLactobacillus brevis、Lactococcus lactis、Lactobacillus hilgardii、Lactobacillus plantarum、Lactobacillus bulgaricus、Lactobacillus delbrueckii、Lactobacillus leichmannii、Lactobacillus helveticus、Lactobacillus acidophilus、Lactobacillus casei、Lactobacillus fermentum、Enterococcus avium、Enterococcus casseliflavus、Streptococcus thermophilus、Streptococcus faecalis、Leuconostoc mesenteroides、Bifidobacterium longumからなる群から選択される一又は複数の乳酸菌である、[4]の製造方法。
[6] 窒素源が酵母エキス、大豆タンパク質、トウモロコシ分解物、小麦分解物、綿花抽出物、及びホエータンパク質からなる群から選択される一又は複数の窒素源である、[4]又は[5]の製造方法。
[7] 培地の培養開始時のpHが4を超える、[4]~[6]のいずれかの製造方法。
[8] 培地がさらに、二価の金属イオンを含む、[4]~[7]のいずれかの製造方法。
[9] 二価の金属イオンがマンガンイオン及び鉄イオンからなる群から選択される一又は複数のイオンである、[8]の製造方法。
[10] 加熱したタマネギが、加熱したタマネギエキスであり、1~10w/v%Brix固形分量を有する、[4]~[9]のいずれかの製造方法。
[11] 乳酸菌発酵タマネギがさらに、シクロアリインを含有する、[4]~[10]のいずれかの製造方法。
The present invention is based on these findings and includes the following aspects.
[1] Lactic acid bacteria-fermented onion containing 5 w/w % or more of γ-aminobutyric acid (GABA) based on the Brix solid content of the onion.
[2] The lactic acid bacteria-fermented onion according to [1], further containing 0.5 w/w % or more of cycloalliin based on the Brix solid content of the onion.
[3] Lactic acid bacteria-fermented onion according to [1] or [2], wherein the onion is an onion extract.
[4] A method for producing a lactic acid bacteria-fermented onion containing GABA, which comprises a step of culturing a lactic acid bacterium having glutamic acid decarboxylase activity in a medium containing heated onion, a nitrogen source, and glutamic acid or a salt thereof.
[5] The lactic acid bacteria is selected from Lactobacillus brevis, Lactococcus lactis, Lactobacillus hilgardii, Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus delbrueckii, Lactobacillus leichmannii, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, Enterococcus avium, Enterococcus casseliflavus, Streptococcus thermophilus, Streptococcus faecalis, Leuconostoc mesenteroides, and Bifidobacterium longum.
[6] The method according to [4] or [5], wherein the nitrogen source is one or more nitrogen sources selected from the group consisting of yeast extract, soy protein, corn hydrolysate, wheat hydrolysate, cotton extract, and whey protein.
[7] The method according to any one of [4] to [6], wherein the pH of the medium at the start of culture is greater than 4.
[8] The method according to any one of [4] to [7], wherein the medium further contains a divalent metal ion.
[9] The method according to [8], wherein the divalent metal ion is one or more ions selected from the group consisting of manganese ions and iron ions.
[10] The method according to any of [4] to [9], wherein the heated onion is a heated onion extract having a Brix solid content of 1 to 10 w/v %.
[11] The method according to any one of [4] to [10], wherein the lactic acid bacteria-fermented onion further contains cycloalliin.
本発明によれば、タマネギを原料としてGABAを生産する方法を提供すると共に、タマネギ中の糖質含量を低減し、シクロアリイン等の機能性成分を富化する方法を提供することができる。 The present invention provides a method for producing GABA using onions as a raw material, as well as a method for reducing the carbohydrate content in onions and enriching them with functional components such as cycloalliin.
本発明により得られる乳酸菌発酵タマネギは、GABAとシクロアリインの二種の機能性成分を高濃度で含有するものであり、医薬又は機能性食品の原料として利用することができ、生活習慣病の予防やQOL(生活の質)向上に貢献することができる。 The lactobacillus-fermented onions obtained by the present invention contain high concentrations of two functional ingredients, GABA and cycloalliin, and can be used as ingredients for medicines or functional foods, contributing to the prevention of lifestyle-related diseases and improving quality of life (QOL).
本発明は、高い含有量にてGABAを含み、かつシクロアリイン等の機能性成分が富化された乳酸菌発酵タマネギの製造法に関し、本方法は加熱したタマネギ、窒素源、及びグルタミン酸もしくはその塩を含む培地中にて、GAD活性を有する乳酸菌を培養し、前記タマネギを乳酸発酵する工程を含む。 The present invention relates to a method for producing lactic acid bacteria-fermented onions that contain a high content of GABA and are enriched with functional components such as cycloalliin, and the method comprises the steps of culturing lactic acid bacteria having GAD activity in a medium containing heated onions, a nitrogen source, and glutamic acid or a salt thereof, and lactic acid fermenting the onions.
本発明において「タマネギ」とは、一般的に食用に供されるタマネギ種(Allium cepa L.)を意味し、その種類は特に限定されず、既存の一般的な春播き栽培タマネギ(例えば、北もみじ2000、北もみじ、札幌黄、ポールスター、ツキヒカリ、北見黄、月光22号、オホーツク等)、秋播き栽培タマネギ(例えば、大阪丸、泉南甲高、泉州中甲黄、さつき、もみじ等)、ならびにそれらの変異株を利用することができる。本発明においてタマネギは、可食部である鱗茎部(一般に、「バルブ」もしくは「球」と呼ばれる部分)又はその乾燥物を利用することができ、鱗茎部の外皮(茶色の薄皮)は含まれないことが好ましい。当該外皮が含まれることにより、最終産物である乳酸菌発酵タマネギ中に含まれるシクロアリインの含有量が低下する場合がある。 In the present invention, "onion" refers to an onion species (Allium cepa L.) that is generally used for food, and the type is not particularly limited. Existing common spring-sown onions (e.g., Kitamomiji 2000, Kitamomiji, Sapporo yellow, Polestar, Tsukihikari, Kitami yellow, Gekko 22, Okhotsk, etc.), autumn-sown onions (e.g., Osaka Maru, Sennan Koko, Senshu Chuko yellow, Satsuki, Momiji, etc.), and mutants thereof can be used. In the present invention, the edible bulb part (the part generally called "bulb" or "sphere") or a dried product thereof can be used as the onion, and it is preferable that the outer skin (thin brown skin) of the bulb part is not included. The inclusion of the outer skin may reduce the content of cycloalliin in the final product, lactic acid bacteria-fermented onion.
本発明において「タマネギ」とは、適当な寸法又は形状にカットした形態、あるいは、破砕、粉砕、又は摩砕した形態であってもよいが、好ましくは、抽出物の形態である。タマネギを抽出物の形態で用いることによって、乳酸菌による効率的な発酵を促すことができる。 In the present invention, "onion" may be in the form of being cut to an appropriate size or shape, or in the form of being crushed, pulverized or ground, but is preferably in the form of an extract. By using onion in the form of an extract, efficient fermentation by lactic acid bacteria can be promoted.
本発明において「抽出物」とは、搾汁、抽出液、又はそれら混合物、あるいは前記搾汁、抽出液又はそれらの混合物の濃縮物や乾燥物を挙げることができる。 In the present invention, "extract" refers to squeezed juice, extract, or a mixture thereof, or a concentrate or dried product of the squeezed juice, extract, or mixture thereof.
「搾汁」は、タマネギを破砕・圧搾して、液体画分と細胞壁等の固体画分とを分離し、液体画分を取得することにより調製することができる。液体画分と固体画分との分離は遠心分離、ろ過(例えば珪藻土ろ過)等の通常の固液分離手段により行うことができる。 The "juice" can be prepared by crushing and squeezing onions, separating the liquid fraction from the solid fraction such as cell walls, and obtaining the liquid fraction. The liquid fraction can be separated from the solid fraction by conventional solid-liquid separation means such as centrifugation or filtration (e.g., diatomaceous earth filtration).
「抽出液」は、タマネギより抽出媒体や水蒸気蒸留法等を用いて抽出することにより調製することができる。抽出媒体としては、有機溶媒、水等の溶媒、超臨界二酸化炭素等の超臨界流体を利用することができる。溶媒としては水や、エタノール等のアルコール、ヘキサン、アセトン等の有機溶媒、あるいはそれらの混合溶媒を用いることができ、好ましくは水、エタノール、もしくはそれらの混合物、又はアセトンであり、特に好ましくは水である。溶媒抽出により抽出液を製造する場合には、タマネギを適量の溶媒(タマネギに対して重量基準で0.5~20倍量、例えば0.5~15倍量もしくは1~10倍量)中に浸漬し、適宜撹拌又は静置して溶媒中に溶媒可溶性成分を溶出させる。抽出時間は特に限定されないが、5分間~360分間、例えば、15分間~240分間もしくは30分間~120分間とすることができる。抽出温度は特に限定されないが、0℃~125℃、例えば25℃~120℃、好ましくは60℃~120℃、より好ましくは70℃~120℃、さらに好ましくは80℃~120℃、特に好ましくは90℃~120℃の範囲にて行うことができる。抽出後、溶媒可溶性成分を含む溶媒画分と細胞壁等の固体画分とを上述の固液分離手段により分離し、溶媒画分を抽出液として取得する。得られた抽出液は必要に応じてさらに、クロマトグラフィー(カラムクロマトグラフィー、ガスクロマトグラフィー、高速液体クロマトグラフィー(HPLC)、超臨界流体クロマトグラフィー等)及び/又は再結晶等の精製手段に付して精製又は粗精製してもよい。抽出に用いるタマネギの形状は、原型のまま、あるいは適当な寸法又は形状にカットした形態、あるいは破砕、粉砕、又は摩砕した形態、あるいは搾汁の形態とすることができる。なお、本明細書中、「抽出液」を「エキス」と記載する場合がある。 The "extract" can be prepared by extraction from onions using an extraction medium or steam distillation. As the extraction medium, an organic solvent, a solvent such as water, or a supercritical fluid such as supercritical carbon dioxide can be used. As the solvent, water, an alcohol such as ethanol, an organic solvent such as hexane or acetone, or a mixture of these can be used, preferably water, ethanol, or a mixture of these, or acetone, and particularly preferably water. When producing an extract by solvent extraction, onions are immersed in an appropriate amount of solvent (0.5 to 20 times the amount of onions by weight, for example 0.5 to 15 times or 1 to 10 times the amount), and appropriately stirred or allowed to stand to elute the solvent-soluble components into the solvent. There is no particular limitation on the extraction time, but it can be 5 to 360 minutes, for example 15 to 240 minutes or 30 to 120 minutes. The extraction temperature is not particularly limited, but can be in the range of 0°C to 125°C, for example, 25°C to 120°C, preferably 60°C to 120°C, more preferably 70°C to 120°C, even more preferably 80°C to 120°C, and particularly preferably 90°C to 120°C. After extraction, the solvent fraction containing the solvent-soluble components and the solid fraction such as cell walls are separated by the above-mentioned solid-liquid separation means, and the solvent fraction is obtained as an extract. If necessary, the obtained extract may be further purified or roughly purified by purification means such as chromatography (column chromatography, gas chromatography, high performance liquid chromatography (HPLC), supercritical fluid chromatography, etc.) and/or recrystallization. The onions used for extraction may be in the original form, cut to an appropriate size or shape, crushed, pulverized, or ground, or squeezed juice. In this specification, the "extract" may be referred to as "extract".
「濃縮物」は、前記搾汁又は抽出液あるいはそれら混合物を濃縮することにより得ることができる。ここで濃縮とは搾汁又は抽出液あるいはこれらの混合物中の液体(水及び/又は抽出溶媒)を減少させて、可溶性固形分の含量(本明細書中、「Brix固形含量」と記載する場合がある)を高めることを指す。「Brix固形含量」は市販の糖度計又はBrix計にて測定することができ、Brix値とも称される。濃縮の方法としては、例えば真空蒸発濃縮、膜濃縮が採用できる。真空蒸発濃縮は一般的に減圧濃縮と呼ばれる。濃縮時の真空度はBrix固形含量を高めることができる範囲で選択でき、特に限定されない。膜濃縮は、例えば逆浸透膜(RO)、限外ろ過膜(UF)等の膜を使用して行うことができる。使用する膜の種類はBrix固形含量を高めることができる範囲で選択でき、特に限定されない。 The "concentrate" can be obtained by concentrating the above-mentioned squeezed juice or extract or a mixture thereof. Here, concentration refers to reducing the liquid (water and/or extraction solvent) in the squeezed juice or extract or a mixture thereof to increase the content of soluble solids (sometimes referred to as "Brix solids content" in this specification). The "Brix solids content" can be measured using a commercially available sugar content meter or Brix meter, and is also called the Brix value. For example, vacuum evaporation concentration and membrane concentration can be used as a method of concentration. Vacuum evaporation concentration is generally called reduced pressure concentration. The degree of vacuum during concentration can be selected within a range that can increase the Brix solids content, and is not particularly limited. Membrane concentration can be performed using a membrane such as a reverse osmosis membrane (RO) or an ultrafiltration membrane (UF). The type of membrane used can be selected within a range that can increase the Brix solids content, and is not particularly limited.
「乾燥物」は、前記搾汁又は抽出液あるいはそれら混合物や前記濃縮物を通常の乾燥手段(凍結乾燥、減圧乾燥、加熱乾燥、風乾等)を用いて乾燥することにより得ることができる。 The "dried product" can be obtained by drying the juice or extract or a mixture thereof or the concentrate using conventional drying methods (freeze drying, vacuum drying, heat drying, air drying, etc.).
本発明においてタマネギは加熱されたものを利用する。加熱されたタマネギにはシクロアリインが含まれるため、加熱したタマネギを使用することによって最終産物である乳酸菌発酵タマネギにシクロアリインを含めることができる。タマネギの加熱処理は、シクロアリインを生成可能な条件範囲より適宜選択することが可能であり、例えば、70℃~120℃、好ましくは80℃~120℃、より好ましくは90℃~120℃にて、15分間~240分間、好ましくは30分間~120分間処理することにより行うことができる。加熱処理は乾式加熱であってもよいし、湿式加熱であってもよい。加熱処理は、乳酸菌を接種する前の任意の段階で行うことができ、本処理は単独で行われてもよいし、あるいは、抽出工程や殺菌工程(培地の殺菌工程を含む)等において供される加熱処理が、本処理を兼ねてもよい。 In the present invention, heated onions are used. Heated onions contain cycloalliin, and therefore, by using heated onions, cycloalliin can be contained in the final product, lactic acid bacteria-fermented onions. The heat treatment of onions can be appropriately selected from the range of conditions that can produce cycloalliin, and can be performed, for example, at 70°C to 120°C, preferably 80°C to 120°C, more preferably 90°C to 120°C, for 15 minutes to 240 minutes, preferably 30 minutes to 120 minutes. The heat treatment may be dry heating or wet heating. The heat treatment can be performed at any stage before inoculation with lactic acid bacteria, and this treatment may be performed alone, or the heat treatment provided in the extraction step or sterilization step (including the sterilization step of the medium) may also serve as this treatment.
加熱したタマネギは、培地中に任意の量で含めることが可能であるが、好ましくは加熱したタマネギ由来のBrix固形含量が、1~10w/v%、好ましくは1~5w/v%、より好ましくは2.5w/v%となる量にて含めることができる。所望の含有量を達成するために、水等の任意の溶媒を加熱したタマネギと一緒に加えて希釈して用いてもよい。加熱したタマネギの量が当該量より多すぎても、また少なすぎても、乳酸菌の生育やGABAの生産が不十分となり、所望の最終産物である乳酸菌発酵タマネギを得ることができない場合がある。 Heated onion can be included in the medium in any amount, but preferably in an amount such that the Brix solid content derived from the heated onion becomes 1 to 10 w/v %, preferably 1 to 5 w/v %, more preferably 2.5 w/v %. In order to achieve a desired content, any solvent such as water may be added together with the heated onion for dilution. If the amount of heated onion is more or less than the above amount, the growth of lactic acid bacteria and the production of GABA may become insufficient, and it may not be possible to obtain the desired final product, lactic acid bacteria-fermented onion.
本発明において「窒素源」とは、アミノ酸やタンパク質等を意味し、乳酸菌培養培地の窒素源として従来公知のものを利用することができる。このような窒素源としては、例えば、酵母エキス、大豆タンパク質、トウモロコシ分解物、小麦分解物、綿花抽出物、ホエータンパク質等が挙げられ(これらに限定はされない)、これらより選択される一又は複数の窒素源を組み合わせて利用することができる。本発明における「窒素源」として、好ましくは酵母エキスである。窒素源として酵母エキスを培地に含めることによって、最終産物である乳酸菌発酵タマネギ中に含まれるGABAの含有量を特に高めることができる。 In the present invention, the term "nitrogen source" refers to amino acids, proteins, etc., and any of those conventionally known as nitrogen sources for lactic acid bacteria culture media can be used. Examples of such nitrogen sources include (but are not limited to) yeast extract, soy protein, corn hydrolysate, wheat hydrolysate, cotton extract, whey protein, etc., and one or more nitrogen sources selected from these can be used in combination. The "nitrogen source" in the present invention is preferably yeast extract. By including yeast extract as a nitrogen source in the medium, the GABA content in the final product, lactic acid bacteria-fermented onion, can be particularly increased.
窒素源は培地に、乳酸発酵においてGABAの生産が可能な任意の量で含めること可能であり、例えば、0.1~5w/v%、好ましくは0.1~2w/v%、より好ましくは0.2~1.5w/v%となる量にて含めることができる。 The nitrogen source can be included in the medium in any amount that allows for the production of GABA in lactic acid fermentation, for example, 0.1 to 5 w/v%, preferably 0.1 to 2 w/v%, and more preferably 0.2 to 1.5 w/v%.
本発明において「グルタミン酸もしくはその塩」は、乳酸発酵においてGABA生成反応における基質として培地に含める。グルタミン酸は、化学的にはアミノ酸の一種であるL-グルタミン酸を意味し、その塩としてはナトリウム塩が挙げられる。グルタミン酸もしくはその塩の由来は限定されず、糖蜜やでんぷんから発酵法により生成されたものや、食品タンパク質を酸や酵素で加水分解して生成されたものを用いてもよいし、あるいは、遊離グルタミン酸を含む調味料、水産加工品、トマト等の食材をグルタミン酸もしくはその塩の供給源として用いてもよい。 In the present invention, "glutamic acid or a salt thereof" is included in the medium as a substrate in the GABA production reaction in lactic acid fermentation. Chemically, glutamic acid means L-glutamic acid, a type of amino acid, and its salts include sodium salts. The origin of glutamic acid or its salts is not limited, and it is possible to use glutamic acid produced by fermentation from molasses or starch, or glutamic acid produced by hydrolyzing food proteins with acids or enzymes, or food ingredients such as seasonings, processed seafood products, and tomatoes that contain free glutamic acid as a source of glutamic acid or its salts.
グルタミン酸もしくはその塩は培地に、乳酸発酵においてGABAの生産が可能な任意の量で含めること可能であり、例えば、0.1~10w/v%、例えば、0.5~5w/v%、又は1~3w/v%となる量にて含めることができる。 Glutamic acid or a salt thereof can be included in the medium in any amount that allows for the production of GABA in lactic acid fermentation, for example, 0.1 to 10 w/v%, e.g., 0.5 to 5 w/v%, or 1 to 3 w/v%.
本発明において培地にはさらに、二価の金属イオンを含めることができる。培地に二価の金属イオンを含めることによって、乳酸菌の生育や発酵活性を増強することができ、最終産物である乳酸菌発酵タマネギ中に含まれるGABAの量を高めることができる。二価の金属イオンとしては、Mn2+、Fe2+、Ca2+、Mg2+、Cu2+、Zn2+等が挙げられ(これらに限定はされない)、これらより選択される一又は複数の二価の金属イオンを組み合わせて利用することができる。二価の金属イオンとして、好ましくはMn2+、Fe2+であり、特に好ましくはMn2+である。二価の金属イオンは、医薬品や飲食品において利用可能な無機塩類又は有機塩類の形態で培地に添加することができる。このような塩類としては、硫酸マンガン、塩化マンガン、塩化第二鉄、及びその水和物等が挙げられる(これらに限定はされない)。 In the present invention, the medium may further contain divalent metal ions. By including divalent metal ions in the medium, it is possible to enhance the growth and fermentation activity of lactic acid bacteria, and to increase the amount of GABA contained in the final product, lactic acid bacteria-fermented onion. Examples of divalent metal ions include (but are not limited to) Mn 2+ , Fe 2+ , Ca 2+ , Mg 2+ , Cu 2+ , Zn 2+ and the like, and one or more divalent metal ions selected from these may be used in combination. Preferred divalent metal ions are Mn 2+ and Fe 2+ , and particularly preferred is Mn 2+ . The divalent metal ions may be added to the medium in the form of inorganic salts or organic salts that can be used in medicines and foods and beverages. Examples of such salts include (but are not limited to) manganese sulfate, manganese chloride, ferric chloride, and hydrates thereof.
二価の金属イオンは培地に、乳酸菌の生育や発酵活性を増強することが可能な任意の量で含めることができ、例えば、0.0001~0.01w/v%、又は0.0005~0.01w/v%、0.001~0.01w/v%となる量にて含めることができる。 Divalent metal ions can be included in the medium in any amount that can enhance the growth and fermentation activity of lactic acid bacteria, for example, 0.0001 to 0.01 w/v%, 0.0005 to 0.01 w/v%, or 0.001 to 0.01 w/v%.
本発明において培地のpH値(培養開始時のpH値を意味する)は、乳酸菌の生育が可能であり、かつ乳酸発酵においてGABAの生産が可能な任意の値とすることが可能である。好ましくは、培地のpH値はpH4を超える値であり、より好ましくはpH5以上(例えば、pH5.1以上、pH5.2以上、pH5.3以上、pH5.4以上、もしくはpH5.5以上)である。培地のpH値の上限は特に限定されないが、pH8以下(例えば、pH7.5以下、pH7.4以下、pH7.3以下、pH7.2以下、pH7.1以下、もしくはpH7以下)とすることができる。一態様において、本発明における培地のpH値は、pH4を超える値、かつpH8以下;pH5以上、かつpH8以下;pH5.1以上、かつpH8以下;pH5.2以上、かつpH8以下;pH5.3以上、かつpH8以下;pH5.4以上、かつpH8以下;又は、pH5.5以上、かつpH8以下とすることができる。また別の態様において、本発明における培地のpH値は、pH4を超える値、かつpH7以下;pH5以上、かつpH7以下;pH5.1以上、かつpH7以下;pH5.2以上、かつpH7以下;pH5.3以上、かつpH7以下;pH5.4以上、かつpH7以下;又は、pH5.5以上、かつpH7以下とすることができる。 In the present invention, the pH value of the medium (meaning the pH value at the start of culture) can be any value at which lactic acid bacteria can grow and GABA can be produced in lactic acid fermentation. Preferably, the pH value of the medium is a value exceeding pH 4, more preferably pH 5 or higher (e.g., pH 5.1 or higher, pH 5.2 or higher, pH 5.3 or higher, pH 5.4 or higher, or pH 5.5 or higher). The upper limit of the pH value of the medium is not particularly limited, but can be pH 8 or lower (e.g., pH 7.5 or lower, pH 7.4 or lower, pH 7.3 or lower, pH 7.2 or lower, pH 7.1 or lower, or pH 7 or lower). In one aspect, the pH value of the medium in the present invention can be a value exceeding pH 4 and pH 8 or lower; pH 5 or higher and pH 8 or lower; pH 5.1 or higher and pH 8 or lower; pH 5.2 or higher and pH 8 or lower; pH 5.3 or higher and pH 8 or lower; pH 5.4 or higher and pH 8 or lower; or pH 5.5 or higher and pH 8 or lower. In another aspect, the pH value of the medium of the present invention can be greater than pH 4 and less than pH 7; greater than pH 5 and less than pH 7; greater than pH 5.1 and less than pH 7; greater than pH 5.2 and less than pH 7; greater than pH 5.3 and less than pH 7; greater than pH 5.4 and less than pH 7; or greater than pH 5.5 and less than pH 7.
一般的に、乳酸発酵を行う場合には、乳酸菌が優先的に増殖できる環境をつくるために培地のpH値は低く設定される(例えばpH4程度)。一方、本発明においては培地のpH値を、pH4を超える値とすることにより、最終産物である乳酸菌発酵タマネギ中に含まれるGABAの含有量を顕著に増大させることができる。 Generally, when lactic acid fermentation is carried out, the pH value of the medium is set low (for example, about pH 4) to create an environment in which lactic acid bacteria can grow preferentially. On the other hand, in the present invention, the pH value of the medium is set to a value exceeding pH 4, thereby making it possible to significantly increase the GABA content in the final product, lactic acid bacteria-fermented onion.
培地のpH値の調整は、医薬品や飲食品において利用可能なpH調整剤を培地に適宜添加することにより行うことができる。このようなpH調整剤としては、例えば、リン酸、DL-リンゴ酸、乳酸ナトリウム、水酸化ナトリウム、炭酸ナトリウム、クエン酸、クエン酸ナトリウム等が挙げられるが、これらに限定はされない。 The pH value of the medium can be adjusted by adding a pH adjuster that can be used in pharmaceuticals and food and beverages to the medium as appropriate. Examples of such pH adjusters include, but are not limited to, phosphoric acid, DL-malic acid, sodium lactate, sodium hydroxide, sodium carbonate, citric acid, and sodium citrate.
培地にはさらに、上記成分に加えて、炭素源、上述のものとは異なる窒素源や無機塩類、動植物のエキス、寒天等のその他の成分を、必要に応じて含めることができる。 In addition to the above components, the medium may contain other components such as a carbon source, a nitrogen source different from those mentioned above, inorganic salts, animal and plant extracts, agar, etc., as necessary.
本発明において培地は、従来公知の手法に準じて調製することができる。すなわち、上述の加熱したタマネギ、窒素源、グルタミン酸もしくはその塩、必要に応じて水等の任意の溶媒、ならびに、必要に応じて、二価の金属イオン、pH調整剤、その他の成分を、上記の量にて適宜配合・混合し、殺菌処理することにより調製することができる。 In the present invention, the medium can be prepared according to a conventional method. That is, the medium can be prepared by appropriately blending and mixing the above-mentioned heated onion, nitrogen source, glutamic acid or a salt thereof, and any solvent such as water as necessary, as well as divalent metal ions, pH adjusters, and other components as necessary, in the amounts described above, and sterilizing the mixture.
本発明において「乳酸菌」は、GAD活性を有する乳酸菌を意味する。「GAD活性」(グルタミン酸脱炭酸酵素活性)とは、L-グルタミン酸より炭酸を除去してGABAを生成する反応を触媒する活性を意味する。本発明において利用可能なGAD活性を有する乳酸菌としては、Lactobacillus属、Enterococcus属、Streptococcus属、Leuconostoc属、Bifidobacterium属に属する乳酸菌が挙げられ(これらに限定はされない)、例えば、Lactobacillus brevis、Lactococcus lactis、Lactobacillus hilgardii、Lactobacillus plantarum、Lactobacillus bulgaricus、Lactobacillus delbrueckii、Lactobacillus leichmannii、Lactobacillus helveticus、Lactobacillus acidophilus、Lactobacillus casei、Lactobacillus fermentum、Enterococcus avium、Enterococcus casseliflavus、Streptococcus thermophilus、Streptococcus faecalis、Leuconostoc mesenteroides、Bifidobacterium longum等に属する乳酸菌が挙げられる(これらに限定はされない)。また、GAD活性を有する限り、これらの変異株も本発明において利用することができる。 In the present invention, "lactic acid bacteria" refers to lactic acid bacteria having GAD activity. "GAD activity" (glutamic acid decarboxylase activity) refers to the activity of catalyzing the reaction of removing carbon dioxide from L-glutamic acid to produce GABA. Lactic acid bacteria having GAD activity that can be used in the present invention include, but are not limited to, lactic acid bacteria belonging to the genera Lactobacillus, Enterococcus, Streptococcus, Leuconostoc, and Bifidobacterium, such as Lactobacillus brevis, Lactococcus lactis, Lactobacillus hilgardii, Lactobacillus plantarum, Lactobacillus bulgaricus, Lactobacillus delbrueckii, and Lactobacillus subtilis. Examples of lactic acid bacteria include, but are not limited to, lactic acid bacteria belonging to Lactobacillus leichmannii, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, Enterococcus avium, Enterococcus casseliflavus, Streptococcus thermophilus, Streptococcus faecalis, Leuconostoc mesenteroides, Bifidobacterium longum, etc. In addition, as long as they have GAD activity, these mutant strains can also be used in the present invention.
本発明において「培養」は、乳酸発酵が可能な従来公知の条件に準じて行うことができる。すなわち、上記培地に上記の乳酸菌を湿菌体重量にて0.005~5w/v%、好ましくは0.01~2w/v%の量で加え、20℃~50℃、好ましくは25℃~42℃にて、嫌気条件下で行う。温度条件は、恒温槽、マントルヒーター、ジャケット等を利用することにより調整することができる。「嫌気条件下」とは、乳酸菌が増殖可能な程度の低酸素環境下を意味し、例えば嫌気チャンバー、嫌気ボックス又は脱酸素剤を入れた密閉容器もしくは袋等を利用することにより、あるいは単に培養容器を密閉することにより、嫌気条件とすることができる。培養は、静置培養、振とう培養、タンク培養等により行うことができ、培養時間は特に制限されないが、例えば3時間~14日間、例えば、6時間~10日間、もしくは12時間~5日間とすることができる。培養は、連続式で行っても、バッチ式で行っても良い。 In the present invention, "culturing" can be performed according to conventionally known conditions that allow lactic acid fermentation. That is, the above-mentioned lactic acid bacteria are added to the above-mentioned medium in an amount of 0.005 to 5 w/v%, preferably 0.01 to 2 w/v%, based on the wet cell weight, and the culture is performed under anaerobic conditions at 20°C to 50°C, preferably 25°C to 42°C. The temperature conditions can be adjusted by using a thermostatic bath, a mantle heater, a jacket, or the like. "Under anaerobic conditions" means a low-oxygen environment in which lactic acid bacteria can grow. For example, anaerobic conditions can be achieved by using an anaerobic chamber, an anaerobic box, or a sealed container or bag containing an oxygen scavenger, or by simply sealing the culture container. The culture can be performed by static culture, shaking culture, tank culture, etc., and the culture time is not particularly limited, but can be, for example, 3 hours to 14 days, for example, 6 hours to 10 days, or 12 hours to 5 days. The culture can be performed continuously or batchwise.
培養の停止(乳酸発酵の停止)は、高温(80℃以上)での短時間(2秒~5分間)処理、pHを下げる等の慣用の手段により行うことができる。 Cultivation can be stopped (lactic acid fermentation can be stopped) by conventional means such as treatment at high temperature (80°C or higher) for a short period of time (2 seconds to 5 minutes) or lowering the pH.
製造された乳酸菌発酵タマネギは、さらに精製工程に供してもよい。精製は通常用いられる固液分離手段(例えば、遠心分離、ろ過等)を用いることができ、液体部(上清、ろ液)を回収することにより行うことができる。 The lactobacillus-fermented onions thus produced may be further subjected to a refining step. The refining can be carried out by using a commonly used solid-liquid separation means (e.g., centrifugation, filtration, etc.) and by recovering the liquid portion (supernatant, filtrate).
製造された乳酸菌発酵タマネギは、必要に応じて、殺菌処理に供してもよい。殺菌は通常用いられる手段(例えば、加熱殺菌、高圧殺菌、気流殺菌等)を用いることができる。乳酸菌発酵タマネギ中の各種成分を保持するために、殺菌処理は、可能なかぎり短時間かつ低温であることが好ましい。 The lactobacillus-fermented onions thus produced may be subjected to a sterilization treatment, if necessary. Sterilization can be performed by any commonly used means (e.g., heat sterilization, high-pressure sterilization, air current sterilization, etc.). In order to preserve the various components in the lactobacillus-fermented onions, it is preferable that the sterilization treatment be performed for as short a time as possible at as low a temperature as possible.
製造された乳酸菌発酵タマネギは、必要に応じて、濃縮物又は乾燥物の形態とすることができる。濃縮は乳酸菌発酵タマネギ中の水分を減少させることにより行うことができる。濃縮の方法としては、上述の真空蒸発濃縮、膜濃縮等を用いることができる。乾燥は乳酸菌発酵タマネギ、又はその濃縮物を通常の乾燥手段(凍結乾燥、減圧乾燥、加熱乾燥、風乾等)を用いて乾燥することにより行うことができる。濃縮又は乾燥に際して、乳酸菌発酵タマネギと賦形剤等の他の成分とを組み合わせて濃縮又は乾燥を行ってもよい。 The lactobacillus-fermented onion thus produced can be in the form of a concentrate or a dry product, if necessary. The concentration can be carried out by reducing the water content in the lactobacillus-fermented onion. The above-mentioned vacuum evaporation concentration, membrane concentration, etc. can be used as the concentration method. The drying can be carried out by drying the lactobacillus-fermented onion or a concentrate thereof by a usual drying means (freeze drying, reduced pressure drying, heat drying, air drying, etc.). When concentrating or drying, the lactobacillus-fermented onion may be combined with other components such as excipients before the concentration or drying.
本発明により製造された乳酸菌発酵タマネギ(以下、「本発明の乳酸菌発酵タマネギ」と記載する)は、高い含有量にてGABAを含み、Brix固形含量当たり5w/w%、6w/w%、7w/w%、8w/w%、9w/w%、10w/w%、11w/w%、12w/w%、13w/w%、14w/w%、もしくは15w/w%、又はそれ以上の量にてGABAを含む。 The lactic acid bacteria-fermented onion produced according to the present invention (hereinafter referred to as "lactic acid bacteria-fermented onion of the present invention") contains a high content of GABA, and contains 5 w/w%, 6 w/w%, 7 w/w%, 8 w/w%, 9 w/w%, 10 w/w%, 11 w/w%, 12 w/w%, 13 w/w%, 14 w/w%, 15 w/w% or more of GABA per Brix solid content.
また、本発明の乳酸菌発酵タマネギは、高い含有量にてシクロアリインを含み、Brix固形含量当たり0.5w/w%、0.6w/w%、0.7w/w%、0.8w/w%、0.9w/w%、もしくは1w/w%、又はそれ以上の量にてシクロアリインを含む。 The lactobacillus-fermented onions of the present invention also contain a high content of cycloalliin, with the amount being 0.5 w/w%, 0.6 w/w%, 0.7 w/w%, 0.8 w/w%, 0.9 w/w%, or 1 w/w% or more of cycloalliin per Brix solid content.
本発明の乳酸菌発酵タマネギにおいては、乳酸発酵の過程でタマネギに含まれる糖質が消費されその含量が低減されるため、Brix固形含量当たりのGABAやシクロアリイン等の機能性成分の含有量を高めることができる。 In the lactobacillus-fermented onion of the present invention, the carbohydrates contained in the onion are consumed during the lactic acid fermentation process, and the carbohydrate content is reduced, so that the content of functional components such as GABA and cycloalliin per Brix solid content can be increased.
本発明の乳酸菌発酵タマネギは、医薬又は飲食品として許容可能な賦形剤、崩壊剤、滑沢剤、結合剤等を含めることができ、所望される剤型や形態へと製造することができる。 The lactobacillus-fermented onion of the present invention can contain excipients, disintegrants, lubricants, binders, etc. that are acceptable for use as medicines or foods and beverages, and can be manufactured into a desired dosage form or shape.
賦形剤としては、例えば、ブドウ糖、デンプン、α化デンプン、デキストリン、D-マンニトール、D-ソルビトール、乳糖、コーンスターチ、結晶セルロース、低置換度ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、アラビアゴム、白糖、プルラン、軽質無水ケイ酸、合成ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム等が挙げられる。 Examples of excipients include glucose, starch, pregelatinized starch, dextrin, D-mannitol, D-sorbitol, lactose, corn starch, crystalline cellulose, low-substituted hydroxypropyl cellulose, sodium carboxymethylcellulose, gum arabic, white sugar, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate, etc.
崩壊剤としては、例えば、デンプン、乳糖、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、白糖、軽質無水ケイ酸、低置換度ヒドロキシプロピルセルロース等が挙げられる。 Examples of disintegrants include starch, lactose, carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, sodium carboxymethylstarch, sucrose, light anhydrous silicic acid, and low-substituted hydroxypropylcellulose.
滑沢剤としては、例えば、ショ糖脂肪酸エステルやグリセリン脂肪酸エステル等のシュガーエステル類、ステアリン酸カルシウム、ステアリン酸マグネシウム、ステアリン酸、ステアリルアルコール、粉末植物油脂等の硬化油、サラシミツロウ等のロウ類、タルク、ケイ酸、ケイ素等が挙げられる。 Examples of lubricants include sugar esters such as sucrose fatty acid esters and glycerin fatty acid esters, calcium stearate, magnesium stearate, stearic acid, stearyl alcohol, hydrogenated oils such as powdered vegetable oils and fats, waxes such as white beeswax, talc, silicic acid, silicon, etc.
結合剤としては、例えば、ショ糖、α化デンプン、ゼラチン、デキストリン、アラビアゴム、メチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースナトリウム、結晶セルロース、白糖、D-マンニトール、トレハロース、プルラン、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン等が挙げられる。 Binders include, for example, sucrose, pregelatinized starch, gelatin, dextrin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.
本発明の乳酸菌発酵タマネギには、必要に応じてさらに、医薬品(医薬部外品を含む)又は飲食品の製造において通常用いられている希釈剤、緩衝剤、懸濁化剤、コーティング剤、保存剤、防腐剤、酸化防止剤、着色剤、凝集防止剤、吸収促進剤、溶剤、溶解補助剤、等張化剤、安定化剤、矯味矯臭剤、pH調整剤、香料、甘味料、呈味成分、酸味料等のその他の成分を、所望される剤型や形態に応じて適宜選択、配合することができる。 If necessary, the lactic acid bacteria-fermented onion of the present invention can further contain other ingredients that are usually used in the production of medicines (including quasi-drugs) or food and drink, such as diluents, buffers, suspending agents, coating agents, preservatives, antiseptics, antioxidants, colorants, anti-aggregating agents, absorption promoters, solvents, solubilizers, isotonicity agents, stabilizers, flavorings, pH adjusters, fragrances, sweeteners, taste-imparting components and acidulants, which can be appropriately selected and blended according to the desired dosage form and shape.
本発明の乳酸菌発酵タマネギは、医薬品(医薬部外品を含む)又は飲食品の形態で提供することができる。 The lactobacillus-fermented onion of the present invention can be provided in the form of a medicine (including quasi-drugs) or a food or drink.
医薬品は、その形態に特に制限はないが、経口に適した形態であることが好ましい。例えば、経口投与用固体組成物(固形医薬製剤)としては、錠剤(糖衣錠を含む)、丸剤、カプセル剤、細粒剤、顆粒剤、トローチ剤、チュアブル剤、ドロップ剤等の形態を、また経口投与用液状組成物(液状医薬製剤)としては、乳濁剤、溶液剤、懸濁剤、シロップ剤などの形態をとることができる。これらの製剤は、本発明の乳酸菌発酵タマネギに加えて、上記賦形剤等やその他の成分をその剤形に応じて、適宜配合し、常法に従って製剤化することができる。 The pharmaceutical preparation is not particularly limited in its form, but is preferably in a form suitable for oral administration. For example, solid compositions for oral administration (solid pharmaceutical preparations) may be in the form of tablets (including sugar-coated tablets), pills, capsules, fine granules, granules, troches, chewable tablets, drops, etc., while liquid compositions for oral administration (liquid pharmaceutical preparations) may be in the form of emulsions, solutions, suspensions, syrups, etc. These preparations can be formulated in the usual manner by appropriately mixing the lactobacillus-fermented onion of the present invention with the above-mentioned excipients and other ingredients according to the dosage form.
医薬品は、GABAによって引き起こされる効能・効果(例えば、血圧降下抑制、精神安定化、睡眠改善等)やシクロアリインによって引き起こされる効能・効果(例えば、血栓性疾患の予防等)を有する旨表示することができる。 Medicines may be labeled as having efficacy and effects caused by GABA (e.g., suppression of blood pressure drops, mental stabilization, improvement of sleep, etc.) or efficacy and effects caused by cycloalliin (e.g., prevention of thrombotic diseases, etc.).
飲食品は、その形態に特に制限はないが、カレー、ミックススパイス(カレー粉、ガラムマサラ等)、ふりかけ、調味料、スープ、洋風煮込み料理(シチュー、チャウダー、ハヤシ、ハッシュドビーフ、ブイヤベース等)、ソース、ドレッシング、スナック、麺(ラーメン、うどん等)、デザート、ジュース、お茶、お酒、錠菓、錠剤、チュアブル錠、粉剤、散剤、カプセル剤、顆粒剤、ドリンク剤等の形態を有する健康飲食品(サプリメント、栄養補助食品、健康補助食品、栄養調整食品等)等が挙げられる。 There are no particular limitations on the form of the food and drink, but examples include curry, mixed spices (curry powder, garam masala, etc.), furikake, seasoning, soup, Western-style simmered dishes (stew, chowder, hayashi, hash brown, bouillabaisse, etc.), sauce, dressing, snacks, noodles (ramen, udon, etc.), desserts, juice, tea, alcohol, tablets, tablets, chewable tablets, powders, powders, capsules, granules, drinks, and other health foods and drinks (supplements, dietary supplements, health supplements, nutritionally adjusted foods, etc.).
飲食品には、一般的な飲食品に加えて、保健機能食品(特定保健用食品(条件付き特定保健用食品を含む)、栄養機能食品、機能性表示食品)や、健康食品等が含まれ、これらの飲食品には、GABAによって引き起こされる効能・効果(例えば、血圧降下抑制、精神安定化、睡眠改善等)やシクロアリインによって引き起こされる効能・効果(例えば、血栓性疾患の予防等)を有する旨表示することができる。
以下、本発明を実施例により、更に詳しく説明する。
In addition to general foods and beverages, foods and beverages include health functional foods (foods for specified health uses (including conditional foods for specified health uses), nutritional functional foods, and foods with functional claims) and health foods, and these foods and beverages can be labeled as having efficacy and effects caused by GABA (e.g., suppression of blood pressure drop, mental stabilization, improvement of sleep, etc.) or efficacy and effects caused by cycloalliin (e.g., prevention of thrombotic diseases, etc.).
The present invention will now be described in more detail with reference to examples.
実施例1:GABA及びシクロアリインを含む乳酸菌発酵タマネギエキスの製造
タマネギの外皮を除いたタマネギ鱗茎部を適当な大きさに細断し、その700gに同量の水を加え、80℃で10分間加熱し抽出した後、上清を回収してタマネギの抽出物(以下、「タマネギエキス」と記載する)を得た(1,300g;Brix固形含量4.9w/v%)。
Example 1 Production of Lactic Acid Bacteria-Fermented Onion Extract Containing GABA and Cycloalliin Onion bulbs from which the outer skin had been removed were cut into suitable sizes, and 700 g of the cut onion bulbs were mixed with the same amount of water and heated at 80° C. for 10 minutes for extraction. The supernatant was then recovered to give an onion extract (hereinafter referred to as "onion extract") (1,300 g; Brix solid content 4.9 w/v %).
次いで、得られたタマネギエキスのBrix固形含量を2.5w/v%に調整した後、当該エキスに対し1w/v%量の粉末酵母エキス(粉末酵母エキスD-3H(日本製薬))及び1w/v%量のグルタミン酸ナトリウム一水和物を添加し、水酸化ナトリウム溶液を添加してpH6.8に調整した後、120℃で20分間オートクレーブ処理した。 Then, the Brix solid content of the obtained onion extract was adjusted to 2.5 w/v %, and then 1 w/v % of powdered yeast extract (Powdered Yeast Extract D-3H (Nihon Seiyaku)) and 1 w/v % of monosodium glutamate monohydrate were added to the extract, sodium hydroxide solution was added to adjust the pH to 6.8, and the mixture was autoclaved at 120°C for 20 minutes.
オートクレーブ処理したタマネギエキスに、予め前培養したLactobacillus brevis NBRC12005株(独立行政法人製品評価技術基盤機構バイオテクノロジーセンター(NBRC)より入手)(以下、「NBRC12005株」と記載する)を1v/v%の割合で接種し、30℃で3日間培養し発酵させた。 The autoclaved onion extract was inoculated with pre-cultured Lactobacillus brevis NBRC12005 strain (obtained from the National Institute of Technology and Evaluation, Biotechnology Center (NBRC)) (hereinafter referred to as "NBRC12005 strain") at a ratio of 1 v/v%, and cultured at 30°C for 3 days to allow fermentation.
培養終了後、得られた乳酸菌発酵タマネギエキスには、Brix固形含量あたりの量として(培養後のBrix固形含量は3.9w/v%)、GABA及びシクロアリインがそれぞれ12w/w%及び0.74w/w%含まれることが確認された。 After the cultivation was completed, it was confirmed that the lactobacillus-fermented onion extract obtained contained 12 w/w% GABA and 0.74 w/w% cycloalliin, respectively, calculated as the amount per Brix solid content (Brix solid content after cultivation was 3.9 w/v%).
実施例2:乳酸菌発酵における窒素源の検討
タマネギの外皮を除いたタマネギ鱗茎部を適当な大きさに細断し、その700gに1400gの水を加え、115℃で30分間加熱し抽出した後、上清を回収してタマネギエキスを得た(2000g;Brix固形含量2.5w/v%)。
Example 2: Investigation of nitrogen source in lactic acid bacteria fermentation Onion bulbs from which the outer skin had been removed were cut into suitable sizes, and 1,400 g of water was added to 700 g of the cut onion bulbs. The mixture was heated at 115° C. for 30 minutes and extracted, and the supernatant was recovered to give an onion extract (2,000 g; Brix solid content 2.5 w/v %).
次いで、得られたタマネギエキスに対し1w/v%量の大豆タンパク加水分解物(Soy peptone F(富士フィルム和光純薬))及び1w/v%量のグルタミン酸ナトリウム一水和物を添加し、水酸化ナトリウム溶液を添加してpH6.8に調整した後、120℃で20分間オートクレーブ処理した。 Next, 1 w/v % of soy protein hydrolysate (Soy peptone F (Fujifilm Wako Pure Chemical Industries, Ltd.)) and 1 w/v % of monosodium glutamate monohydrate were added to the onion extract obtained, and the pH was adjusted to 6.8 by adding sodium hydroxide solution, followed by autoclaving at 120°C for 20 minutes.
オートクレーブ処理したタマネギエキスに、予め前培養したNBRC12005株を1v/v%の割合で接種し、30℃で3日間培養し発酵させた。 The autoclaved onion extract was inoculated with pre-cultured NBRC12005 strain at a ratio of 1 v/v %, and cultured at 30°C for 3 days to allow fermentation.
培養終了後、得られた乳酸菌発酵タマネギエキスには、Brix固形含量あたりの量として(培養後のBrix固形含量は4.0w/v%)、GABA及びシクロアリインがそれぞれ6w/w%および0.5w/w%含まれることが確認された。この結果より、粉末酵母エキスに代えて、大豆タンパク加水分解物を窒素源として用いた場合においても、GABA及びシクロアリインを高い割合で含む乳酸菌発酵タマネギエキスが得られることが確認された。 After the completion of the cultivation, it was confirmed that the obtained lactic acid bacteria-fermented onion extract contained 6 w/w% GABA and 0.5 w/w% cycloalliin, respectively, calculated as the amount per Brix solid content (Brix solid content after cultivation was 4.0 w/v%). From these results, it was confirmed that even when soybean protein hydrolysate was used as the nitrogen source instead of powdered yeast extract, a lactic acid bacteria-fermented onion extract containing GABA and cycloalliin at high rates could be obtained.
実施例3:乳酸菌発酵における窒素源添加による効果
添加する粉末酵母エキスの量を除いて、上記実施例1に記載される手法にてオートクレーブ処理したタマネギエキスを調製した。粉末酵母エキスは、0w/v%、0.25w/v%、0.5w/v%、又は1w/v%の量にて添加した。
Example 3 Effect of Addition of Nitrogen Source on Lactic Acid Bacteria Fermentation Autoclaved onion extracts were prepared in the same manner as in Example 1 except for the amount of powdered yeast extract added. The powdered yeast extract was added in amounts of 0 w/v %, 0.25 w/v %, 0.5 w/v % or 1 w/v %.
次いで、予め前培養したNBRC12005株又はLactobacillus brevis NBRC3345株(NBRCより入手)(以下、「NBRC3345株」と記載する)をそれぞれ1v/v%の割合で接種し、30℃で2日間培養し発酵させた。 Next, the NBRC12005 strain or Lactobacillus brevis NBRC3345 strain (obtained from NBRC) (hereinafter referred to as "NBRC3345 strain") that had been precultured in advance was inoculated at a ratio of 1 v/v%, and cultured at 30°C for 2 days to allow fermentation.
培養終了後、各乳酸菌発酵タマネギエキスにおけるGABAの含有量に基づいて、グルタミン酸ナトリウム一水和物からの変換率を算出した。 After the cultivation was completed, the conversion rate from monosodium glutamate monohydrate was calculated based on the GABA content in each lactobacillus-fermented onion extract.
結果を図1に示す。NBRC12005株及びNBRC3345株のいずれにおいても、粉末酵母エキスを添加することによってGABAの産生が確認された。一方、タマネギには乳酸菌が資化することが可能な窒素源が乏しいために、利用できる窒素源が培地中に十分に存在しない場合にはGABAの産生が行われないことが確認された。 The results are shown in Figure 1. In both the NBRC12005 and NBRC3345 strains, the addition of powdered yeast extract was confirmed to result in the production of GABA. On the other hand, because onions are poor in nitrogen sources that can be assimilated by lactic acid bacteria, it was confirmed that GABA is not produced when there is an insufficient amount of usable nitrogen source in the medium.
実施例4:乳酸菌発酵における二価金属イオン添加による効果
二価金属イオン(Mn2+イオン)源として硫酸マンガン四水和物を添加することを除いて、上記実施例1に記載される手法にてオートクレーブ処理したタマネギエキスを調製した。硫酸マンガン四水和物は0.001w/v%の濃度となるように添加した。
Example 4 Effect of Addition of Divalent Metal Ions on Lactic Acid Bacteria Fermentation An autoclaved onion extract was prepared in the same manner as in Example 1, except that manganese sulfate tetrahydrate was added as a source of divalent metal ions ( Mn ions). Manganese sulfate tetrahydrate was added to a concentration of 0.001 w/v %.
次いで、予め前培養したNBRC12005株又はNBRC3345株をそれぞれ1v/v%の割合で接種し、30℃で2日間培養し発酵させた。 Next, the NBRC12005 strain or NBRC3345 strain, which had been precultured in advance, was inoculated at a ratio of 1 v/v%, and cultured at 30°C for 2 days to allow fermentation.
培養終了後、各乳酸菌発酵タマネギエキスにおけるGABAの含有量に基づいて、グルタミン酸ナトリウム一水和物からの変換率を算出した。 After the cultivation was completed, the conversion rate from monosodium glutamate monohydrate was calculated based on the GABA content in each lactobacillus-fermented onion extract.
結果を図2に示す。NBRC12005株及びNBRC3345株のいずれにおいても、粉末酵母エキスを添加することによってGABAの産生量が向上することが確認された。乳酸発酵時に微量金属としてMn2+イオンを添加することによって乳酸菌の生育及び発酵活性が上昇することが報告されている(Cheng X.ら、Appl Biochem Biotechnol.Nov;174(5):1752-60(2014))。タマネギエキスにはMn2+イオンがほとんど含まれていないことから、Mn2+イオンをタマネギエキスに添加することによって、乳酸菌の生育及び発酵活性を向上させ、それによってGABAの生産性が向上したことが示唆される。 The results are shown in Figure 2. It was confirmed that the addition of powdered yeast extract improved the amount of GABA produced in both the NBRC12005 strain and the NBRC3345 strain. It has been reported that the addition of Mn 2+ ions as a trace metal during lactic acid fermentation increases the growth and fermentation activity of lactic acid bacteria (Cheng X. et al., Appl Biochem Biotechnol. Nov; 174(5):1752-60(2014)). Since onion extract contains almost no Mn 2+ ions, it is suggested that the addition of Mn 2+ ions to onion extract improved the growth and fermentation activity of lactic acid bacteria, thereby improving the productivity of GABA.
実施例5:乳酸菌発酵によるシクロアリインの割合増強
上記実施例1に記載される手法にてオートクレーブ処理したタマネギエキスを調製し、これに予め前培養したNBRC3345株を1v/v%の割合で接種し、30℃で2日間培養し発酵させた。
Example 5 Increase in Proportion of Cycloalliin by Lactic Acid Bacteria Fermentation An autoclaved onion extract was prepared by the method described in Example 1 above, and the pre-cultured NBRC3345 strain was inoculated into this at a ratio of 1 v/v %, and cultured at 30° C. for 2 days to allow fermentation.
培養終了後、得られた乳酸菌発酵タマネギエキスにおけるシクロアリイン含量、Brix固形分量を計測し、固形分あたりのシクロアリイン含量を算出した。
結果を下記表1に示す。
After the cultivation was finished, the cycloalliin content and the Brix solid content in the obtained lactic acid bacteria-fermented onion extract were measured, and the cycloalliin content per solid content was calculated.
The results are shown in Table 1 below.
発酵後のタマネギエキスにおいては、発酵前のタマネギエキスと比べて、シクロアリイン含量の増大が認められると共に、Brix固形分量の減少が認められ、Brix固形分量あたりのシクロアリイン含量の増大(1.3倍)が確認された。 In the onion extract after fermentation, an increase in the cycloalliin content was observed and a decrease in the Brix solid content was observed compared to the onion extract before fermentation, confirming an increase in the cycloalliin content per Brix solid content (1.3 times).
タマネギエキスの乳酸発酵においては、タマネギに含まれる糖質を菌が資化・分解することで糖質を外添せずに発酵を行うことができる。糖質の分解によりタマネギエキス中のBrix固形分量が減少することから、Brix固形分量当たりのシクロアリイン含量の増大が確認された。従来、タマネギに含まれているシクロアリイン等の機能性成分の含量が、乳酸発酵を経てどのように変化するのか明らかにされていなかった。本実施例の結果より、乳酸発酵を利用することにより、シクロアリインやGABA等の機能性成分の含有率を高めることが可能であることが示された。 In the lactic acid fermentation of onion extract, bacteria assimilate and decompose the carbohydrates contained in onions, so that fermentation can be carried out without adding carbohydrates externally. Since the Brix solid content in onion extract decreases due to the decomposition of carbohydrates, an increase in the cycloalliin content per Brix solid content was confirmed. Until now, it was not clear how the content of functional components such as cycloalliin contained in onions changes through lactic acid fermentation. The results of this example showed that it is possible to increase the content of functional components such as cycloalliin and GABA by utilizing lactic acid fermentation.
実施例6:乳酸菌発酵におけるpHの検討
調整後のpH値が異なることを除いて、上記実施例1に記載される手法にてオートクレーブ処理したタマネギエキスを調製した。pH値は水酸化ナトリウム溶液又は塩酸を用いて、pH4、pH5、pH6、又はpH7に調整した。
Example 6: Investigation of pH in lactic acid bacteria fermentation Autoclaved onion extracts were prepared in the same manner as in Example 1 except that the adjusted pH values were different. The pH values were adjusted to pH 4, pH 5, pH 6 or pH 7 with a sodium hydroxide solution or hydrochloric acid.
次いで、予め前培養したNBRC12005株又はNBRC3345株をそれぞれ1v/v%の割合で接種し、30℃で2日間培養し発酵させた。 Next, the NBRC12005 strain or NBRC3345 strain, which had been precultured in advance, was inoculated at a ratio of 1 v/v%, and cultured at 30°C for 2 days to allow fermentation.
培養終了後、各乳酸菌発酵タマネギエキスにおけるGABAの含有量に基づいて、グルタミン酸ナトリウム一水和物からの変換率を算出した。 After the cultivation was completed, the conversion rate from monosodium glutamate monohydrate was calculated based on the GABA content in each lactobacillus-fermented onion extract.
結果を図3に示す。NBRC12005株及びNBRC3345株のいずれにおいても、pH4~pH7においてGABAの生産が確認された。特に、酸性条件(pH4)よりも、比較的高いpH条件(pH5~pH7)において高いGABA生産量が確認された。 The results are shown in Figure 3. GABA production was confirmed at pH 4 to pH 7 for both NBRC12005 and NBRC3345 strains. In particular, higher GABA production was confirmed under relatively high pH conditions (pH 5 to pH 7) than under acidic conditions (pH 4).
乳酸菌は酸性条件において生育可能であることから、優先的に増殖可能な酸性条件にて乳酸発酵を行うことがさせることが一般的である。一方、乳酸菌を用いたGABA生産においては、乳酸菌が増殖可能であると共に、GABA生産酵素であるGADの活性が至適になるpH条件にて培養を行うことが好ましいと考えられる。そのため、発酵開始時のpHが5~7の範囲においてタマネギエキス中で効率良くGABAが生産されると考えられる。
Since lactic acid bacteria can grow under acidic conditions, lactic acid fermentation is generally carried out under acidic conditions where they can grow preferentially. On the other hand, in the production of GABA using lactic acid bacteria, it is considered preferable to culture the lactic acid bacteria under pH conditions where the lactic acid bacteria can grow and where the activity of GAD, a GABA-producing enzyme, becomes optimal. Therefore, it is considered that GABA is efficiently produced in onion extract when the pH at the start of fermentation is in the range of 5 to 7.
Claims (6)
The method according to any one of claims 1 to 5 , wherein the lactic acid bacteria-fermented onion further contains cycloalliin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020069744A JP7464940B2 (en) | 2020-04-08 | 2020-04-08 | Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020069744A JP7464940B2 (en) | 2020-04-08 | 2020-04-08 | Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021164436A JP2021164436A (en) | 2021-10-14 |
JP7464940B2 true JP7464940B2 (en) | 2024-04-10 |
Family
ID=78021200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020069744A Active JP7464940B2 (en) | 2020-04-08 | 2020-04-08 | Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7464940B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7412016B2 (en) | 2021-10-20 | 2024-01-12 | 株式会社ナリヒラ | Manufacturing method for processed tea leaves |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097222A (en) | 2003-08-26 | 2005-04-14 | Toyo Shinyaku:Kk | Fermented product of allium cepa l. |
JP2006256969A (en) | 2005-03-15 | 2006-09-28 | Toyo Shinyaku:Kk | Blood flow ameliorant |
JP2007236271A (en) | 2006-03-08 | 2007-09-20 | Unitika Ltd | METHOD FOR PRODUCING COMPOSITION RICHLY CONTAINING gamma-AMINOBUTYRIC ACID |
-
2020
- 2020-04-08 JP JP2020069744A patent/JP7464940B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005097222A (en) | 2003-08-26 | 2005-04-14 | Toyo Shinyaku:Kk | Fermented product of allium cepa l. |
JP2006256969A (en) | 2005-03-15 | 2006-09-28 | Toyo Shinyaku:Kk | Blood flow ameliorant |
JP2007236271A (en) | 2006-03-08 | 2007-09-20 | Unitika Ltd | METHOD FOR PRODUCING COMPOSITION RICHLY CONTAINING gamma-AMINOBUTYRIC ACID |
Also Published As
Publication number | Publication date |
---|---|
JP2021164436A (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060257454A1 (en) | Conjugated fatty acid esters | |
JP4815493B2 (en) | Medium composition containing fermented gochujang, brewed soy sauce stock or acid-decomposed soy sauce stock, and method for producing γ-aminobutyric acid | |
JP4163631B2 (en) | Fermentation composition of spicy varieties of chili pepper and its use | |
WO2005092122A1 (en) | Composition comprising yucca extract, quillaia extract and lactic acid bacterium and food and drink containing the composition | |
CN101300341B (en) | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation | |
JP4137349B2 (en) | Method for producing food material containing high amount of γ-aminobutyric acid and food material obtained thereby | |
JP2008017703A (en) | METHOD FOR PRODUCING FOOD COMPRISING gamma-AMINOBUTYRIC ACID AND ORNITHINE | |
JP5011543B2 (en) | Method for producing fermented material containing GABA | |
US20100040732A1 (en) | Compositions and Methods for Fermented Nutraceuticals | |
JP2010252660A (en) | Seaweed fermented composition and method for producing the same | |
KR20120095361A (en) | Lactic acid bacterium proliferation promoter | |
JP7464940B2 (en) | Onions enriched with γ-aminobutyric acid and cycloalliin and method for producing the same | |
JP5408927B2 (en) | Method for producing γ-aminobutyric acid | |
JP2008050269A (en) | Oral ingestion material | |
JP5422200B2 (en) | Liver dysfunction improving agent | |
JP2007126399A (en) | Composition for increasing glutathione | |
WO2009099139A1 (en) | Liver-function-improving agent, tool for production of the agent, and use of the agent or the tool | |
JP6968540B2 (en) | Oral composition | |
KR20110010433A (en) | The preparing method for soybean milk with natural gaba using serial fermentation of plant originated lactic acid bacteria with gaba-producing ability and protease-producing ability | |
JP2005323596A (en) | Method for producing vitamin k by culture of unnan sl-001 strain | |
KR102621766B1 (en) | Method for producing fermented antler extract having anti-aging, antibacterial and anti-inflammatory activity, extract obtained therefrom, and use of such extract | |
JP4803971B2 (en) | Lipid metabolism improving composition | |
WO2017047776A1 (en) | Blood tryptophan concentration elevation inhibitor | |
JP2007308404A (en) | Composition having immunomodulatory action | |
JP2006204259A (en) | FERMENTED ACEROLA PRODUCT CONTAINING LARGE AMOUNT OF gamma-AMINOBUTYRIC ACID AND METHOD FOR PRODUCING THE SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230718 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230912 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240130 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240131 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240312 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240319 |